Nanovaccines with cell-derived components for cancer immunotherapy

• Published in: Advanced drug delivery reviews Vol. 182; p. 114107
• Main Authors: Meng, Zhouqi, Zhang, Yaojia, Zhou, Xuanfang, Ji, Jiansong, Liu, Zhuang
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2022
• Subjects: Antigen Presentation - immunology; Antigens, Neoplasm - immunology; Biomimetics - methods; Blood Cells - metabolism; Cancer immunotherapy; Cancer Vaccines - administration & dosage; Cancer Vaccines - immunology; Cell lysates; Cell membranes-based nanovaccine; Cell-derived nanovesicles; Clinical Trials as Topic; Humans; Nanoparticle Drug Delivery System - chemistry; Nanovaccine; Neoplasms - drug therapy; Whole cell vaccine; Nanovaccine; Whole cell vaccine; Cancer immunotherapy; Cell-derived nanovesicles; Cell membranes-based nanovaccine; Cell lysates
• ISSN: 0169-409X; 1872-8294; 1872-8294
• DOI: 10.1016/j.addr.2021.114107

[Display omitted] Cancer nanovaccines as one of immunotherapeutic approaches are able to attack tumors by stimulating tumor-specific immunological responses. However, there still exist multiple challenges to be tackled for cancer nanovaccines to evoke potent antitumor immunity. Particularly, the administration of exogenous materials may cause the off-target immunotherapy responses. In recent years, biomimetic nanovaccines by using cell lysates, cell-derived nanovesicles, or extracted cell membranes as the functional components have received extensive attention. Such nanovaccines based on cell-derived components would show many unique advantages including inherent biocompatibility and the ability to trigger immune responses against a range of tumor-associated antigens. In this review article, we will introduce the recent research progresses of those cell-derived biomimetic nanovaccines for cancer immunotherapy, and discuss the perspectives and challenges associated with the future clinical translation of these emerging vaccine platforms.